vs
Amneal Pharmaceuticals, Inc.（AMRX）与RXO, Inc.（RXO）财务数据对比。点击上方公司名可切换其他公司
RXO, Inc.的季度营收约是Amneal Pharmaceuticals, Inc.的1.8倍（$1.5B vs $814.3M），Amneal Pharmaceuticals, Inc.净利率更高（4.3% vs -3.1%，领先7.4%），Amneal Pharmaceuticals, Inc.同比增速更快（11.5% vs -11.9%），Amneal Pharmaceuticals, Inc.自由现金流更多（$108.5M vs $-9.0M），过去两年RXO, Inc.的营收复合增速更高（26.8% vs 11.1%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
RXO是总部位于美国的头部运输及物流解决方案供应商，核心业务覆盖货运经纪、大件商品最后一公里配送、运输管理服务与全链路供应链优化支持，主要服务北美制造业、零售业及电商领域的客户。
AMRX vs RXO — 直观对比
营收规模更大
RXO
是对方的1.8倍
$814.3M
营收增速更快
AMRX
高出23.3%
-11.9%
净利率更高
AMRX
高出7.4%
-3.1%
自由现金流更多
AMRX
多$117.5M
$-9.0M
两年增速更快
RXO
近两年复合增速
11.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $814.3M | $1.5B |
| 净利润 | $35.1M | $-46.0M |
| 毛利率 | 36.5% | — |
| 营业利润率 | 13.8% | -2.9% |
| 净利率 | 4.3% | -3.1% |
| 营收同比 | 11.5% | -11.9% |
| 净利润同比 | 212.9% | -84.0% |
| 每股收益（稀释后） | $0.10 | $-0.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXRXO
| Q4 25 | $814.3M | $1.5B | ||
| Q3 25 | $784.5M | $1.4B | ||
| Q2 25 | $724.5M | $1.4B | ||
| Q1 25 | $695.4M | $1.4B | ||
| Q4 24 | $730.5M | $1.7B | ||
| Q3 24 | $702.5M | $1.0B | ||
| Q2 24 | $701.8M | $930.0M | ||
| Q1 24 | $659.2M | $913.0M |
净利润AMRXRXO
| Q4 25 | $35.1M | $-46.0M | ||
| Q3 25 | $2.4M | $-14.0M | ||
| Q2 25 | $22.4M | $-9.0M | ||
| Q1 25 | $12.2M | $-31.0M | ||
| Q4 24 | $-31.1M | $-25.0M | ||
| Q3 24 | $-156.0K | $-243.0M | ||
| Q2 24 | $6.0M | $-7.0M | ||
| Q1 24 | $-91.6M | $-15.0M |
毛利率AMRXRXO
| Q4 25 | 36.5% | — | ||
| Q3 25 | 34.9% | — | ||
| Q2 25 | 39.5% | — | ||
| Q1 25 | 36.8% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 38.4% | — | ||
| Q2 24 | 35.6% | — | ||
| Q1 24 | 36.1% | — |
营业利润率AMRXRXO
| Q4 25 | 13.8% | -2.9% | ||
| Q3 25 | 9.0% | -0.5% | ||
| Q2 25 | 15.4% | — | ||
| Q1 25 | 14.4% | -2.1% | ||
| Q4 24 | 10.4% | -1.4% | ||
| Q3 24 | 12.6% | -1.9% | ||
| Q2 24 | 13.6% | — | ||
| Q1 24 | -1.6% | -1.3% |
净利率AMRXRXO
| Q4 25 | 4.3% | -3.1% | ||
| Q3 25 | 0.3% | -1.0% | ||
| Q2 25 | 3.1% | -0.6% | ||
| Q1 25 | 1.8% | -2.2% | ||
| Q4 24 | -4.3% | -1.5% | ||
| Q3 24 | -0.0% | -23.4% | ||
| Q2 24 | 0.9% | -0.8% | ||
| Q1 24 | -13.9% | -1.6% |
每股收益（稀释后）AMRXRXO
| Q4 25 | $0.10 | $-0.28 | ||
| Q3 25 | $0.01 | $-0.08 | ||
| Q2 25 | $0.07 | $-0.05 | ||
| Q1 25 | $0.04 | $-0.18 | ||
| Q4 24 | $-0.10 | $-0.17 | ||
| Q3 24 | $0.00 | $-1.81 | ||
| Q2 24 | $0.02 | $-0.06 | ||
| Q1 24 | $-0.30 | $-0.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.0M | $17.0M |
| 总债务越低越好 | $2.6B | $387.0M |
| 股东权益账面价值 | $-70.8M | $1.5B |
| 总资产 | $3.7B | $3.3B |
| 负债/权益比越低杠杆越低 | — | 0.25× |
8季度趋势，按日历期对齐
现金及短期投资AMRXRXO
| Q4 25 | $282.0M | $17.0M | ||
| Q3 25 | $201.2M | $25.0M | ||
| Q2 25 | $71.5M | $18.0M | ||
| Q1 25 | $59.2M | $16.0M | ||
| Q4 24 | $110.6M | $35.0M | ||
| Q3 24 | $74.0M | $55.0M | ||
| Q2 24 | $43.8M | $7.0M | ||
| Q1 24 | $46.5M | $7.0M |
总债务AMRXRXO
| Q4 25 | $2.6B | $387.0M | ||
| Q3 25 | $2.6B | $387.0M | ||
| Q2 25 | $2.2B | $387.0M | ||
| Q1 25 | $2.2B | $387.0M | ||
| Q4 24 | $2.4B | $351.0M | ||
| Q3 24 | $2.4B | $352.0M | ||
| Q2 24 | $2.4B | $370.0M | ||
| Q1 24 | $2.4B | $351.0M |
股东权益AMRXRXO
| Q4 25 | $-70.8M | $1.5B | ||
| Q3 25 | $-109.5M | $1.6B | ||
| Q2 25 | $-112.1M | $1.6B | ||
| Q1 25 | $-131.7M | $1.6B | ||
| Q4 24 | $-109.3M | $1.6B | ||
| Q3 24 | $-93.4M | $1.7B | ||
| Q2 24 | $-57.5M | $579.0M | ||
| Q1 24 | $-63.7M | $582.0M |
总资产AMRXRXO
| Q4 25 | $3.7B | $3.3B | ||
| Q3 25 | $3.6B | $3.2B | ||
| Q2 25 | $3.4B | $3.2B | ||
| Q1 25 | $3.4B | $3.3B | ||
| Q4 24 | $3.5B | $3.4B | ||
| Q3 24 | $3.5B | $3.4B | ||
| Q2 24 | $3.5B | $1.8B | ||
| Q1 24 | $3.5B | $1.8B |
负债/权益比AMRXRXO
| Q4 25 | — | 0.25× | ||
| Q3 25 | — | 0.24× | ||
| Q2 25 | — | 0.24× | ||
| Q1 25 | — | 0.24× | ||
| Q4 24 | — | 0.22× | ||
| Q3 24 | — | 0.21× | ||
| Q2 24 | — | 0.64× | ||
| Q1 24 | — | 0.60× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $130.3M | $7.0M |
| 自由现金流经营现金流 - 资本支出 | $108.5M | $-9.0M |
| 自由现金流率自由现金流/营收 | 13.3% | -0.6% |
| 资本支出强度资本支出/营收 | 2.7% | 1.1% |
| 现金转化率经营现金流/净利润 | 3.72× | — |
| 过去12个月自由现金流最近4个季度 | $269.9M | $-8.0M |
8季度趋势，按日历期对齐
经营现金流AMRXRXO
| Q4 25 | $130.3M | $7.0M | ||
| Q3 25 | $118.5M | $23.0M | ||
| Q2 25 | $83.8M | $23.0M | ||
| Q1 25 | $7.4M | $-2.0M | ||
| Q4 24 | $118.1M | $-7.0M | ||
| Q3 24 | $141.8M | $-7.0M | ||
| Q2 24 | $39.7M | $-5.0M | ||
| Q1 24 | $-4.4M | $7.0M |
自由现金流AMRXRXO
| Q4 25 | $108.5M | $-9.0M | ||
| Q3 25 | $106.2M | $9.0M | ||
| Q2 25 | $61.0M | $9.0M | ||
| Q1 25 | $-5.8M | $-17.0M | ||
| Q4 24 | $102.9M | $-19.0M | ||
| Q3 24 | $124.8M | $-18.0M | ||
| Q2 24 | $29.0M | $-16.0M | ||
| Q1 24 | $-13.6M | $-4.0M |
自由现金流率AMRXRXO
| Q4 25 | 13.3% | -0.6% | ||
| Q3 25 | 13.5% | 0.6% | ||
| Q2 25 | 8.4% | 0.6% | ||
| Q1 25 | -0.8% | -1.2% | ||
| Q4 24 | 14.1% | -1.1% | ||
| Q3 24 | 17.8% | -1.7% | ||
| Q2 24 | 4.1% | -1.7% | ||
| Q1 24 | -2.1% | -0.4% |
资本支出强度AMRXRXO
| Q4 25 | 2.7% | 1.1% | ||
| Q3 25 | 1.6% | 1.0% | ||
| Q2 25 | 3.2% | 1.0% | ||
| Q1 25 | 1.9% | 1.0% | ||
| Q4 24 | 2.1% | 0.7% | ||
| Q3 24 | 2.4% | 1.1% | ||
| Q2 24 | 1.5% | 1.2% | ||
| Q1 24 | 1.4% | 1.2% |
现金转化率AMRXRXO
| Q4 25 | 3.72× | — | ||
| Q3 25 | 50.00× | — | ||
| Q2 25 | 3.74× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 6.62× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
| Oral Solid | $188.7M | 23% |
| Distribution Service | $107.7M | 13% |
| Central Nervous System | $104.8M | 13% |
| Government Label | $86.8M | 11% |
| Other Dosage Forms | $68.2M | 8% |
| Transdermal | $56.1M | 7% |
| Hormonal Allergy | $47.6M | 6% |
| Ephinephrine Auto Injector | $39.1M | 5% |
| Injectable | $37.4M | 5% |
| Other | $33.6M | 4% |
| Biosimilar | $29.4M | 4% |
| Selling General And Administrative Expenses | $14.9M | 2% |
RXO
| Retail Sector | $546.0M | 37% |
| Last Mile | $298.0M | 20% |
| Food And Beverage Sector | $225.0M | 15% |
| Other Sector | $185.0M | 13% |
| Managed Transportation | $133.0M | 9% |
| Automotive Sector | $93.0M | 6% |
